Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. oralis

Oralis SIGNED

Oralis, The first oral human insulin treatment for Type 2 Diabetes Mellitus

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Oralis project word cloud

Explore the words cloud of the Oralis project. It provides you a very rough idea of what is the project "Oralis" about.

first    pod    prognosis    worth    sme    300    caring    transform    longer    life    lives    century    huge    pain    49    oral    patient    stigma    billion    opens    overcome    5000    prevention    finalise    quality    daily    glucose    share    trial    liver    efficacy    415m    disease    trials    multiple    commercialise    demonstrated    clinical    capability    last    individuals    co    burden    oramed    pharmaceuticals    injecting    people    orally    creation    injectable    commercial    market    type    global    injected    concentration    morbidities    generate    bn    insulin    eventual    bgl    gt    revenue    649    49m    doses    considerable    thousands    region    proven    options    tract    protein    diabetes    annually    levels    therapies    globally    estimation    lifespans    solution    adherence    social    t2dm    agreements    patients    gastrointestinal    treatment    bioavailable    mellitus    trade    instrument    hundreds    2020    61    est    created    paradigm    harsh    newest    protects    glycaemic    claim    blood    sufficient    oralis    181m    confirm    injections   

Project "Oralis" data sheet

The following table provides information about the project.

Coordinator		 ORAMED LTD 

Organization address
address: ELZA ST 2
city: JERUSALEM
postcode: 9370648
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Israel [IL]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ORAMED LTD IL (JERUSALEM) coordinator 50˙000.00

Map

 Project objective

Type 2 Diabetes Mellitus (T2DM) affects 415M people globally, 49M of them within Europe. Caring for these individuals costs Europe €181M billion annually. However, more needs to be done as T2DM and its related co-morbidities claim hundreds of thousands of lives each year in the region. The early control of blood glucose levels (BGL) is the key to the prevention of the disease, and longer lifespans with better prognosis and higher quality of life for T2DM patients. The last century has seen considerable development in T2DM treatment, but the eventual solution to control BGL for many patients are multiple daily insulin injections. This has created a huge global market to be worth €49 billion (est. 2020). The pain, social stigma, and burden associated with injecting insulin contribute to a non-adherence to treatment that has been estimated to be as high as 61%, at a cost 9,649€ per patient per year. Oramed Pharmaceuticals (Oramed) will transform this paradigm with its POD™ technology. It protects protein therapies like insulin from the harsh conditions in the gastrointestinal tract, allowing then to be taken orally. This opens a way into oral insulin treatment to overcome many of the issues contributing to non-adherence of injected insulin treatment in T2DM patients. Using POD™ technology Oramed has produced the first oral insulin and demonstrated its efficacy in Phase II clinical trials with >300 patients and >5000 doses. We have proven oralis capability to deliver to the liver bioavailable insulin at sufficient concentration to produce significant glucose control in all glycaemic parameters in T2DM patients. Through the SME instrument Oramed will finalise the Phase III clinical trial to confirm the efficacy of oralis for glycaemic control in T2DM patients. We have already reach commercial agreements to commercialise oralis. Our estimation is to generate a similar revenue creation and market share as the newest injectable insulin options of €1.7 bn in 5 years.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ORALIS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ORALIS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

Primavera (2018)

Primavera: immunobiotics for treating early stage Age-related Macular Degeneration (AMD)

Read More  

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat

Read More